{"success":true,"data":{"pressRelease":{"id":"5715","rtpr_id":"nGNX35Fh38","ticker":"XCUR","exchange":"NASDAQ","all_tickers":["XCUR"],"title":"Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)","author":"Globe Newswire","published_at":"2026-04-22T23:54:21.097Z","article_body":"CHICAGO, April 22, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) today\nannounced that it has entered into a co-development agreement with Adbiotech\nCo., Ltd. (KOSDAQ: 179530), a Korea-based biotechnology company, to explore\ncombination therapies based on Burixafor (GPC-100) across multiple therapeutic\nareas.\n\nThe collaboration will focus on evaluating combination strategies involving\nBurixafor (GPC-100) in indications including sickle cell disease (SCD), acute\nmyeloid leukemia (AML), and solid tumors.\n\nUnder the agreement, Adbiotech will conduct in vivo studies and support\npreclinical validation and translational research, while Exicure will provide\nBurixafor and lead clinical and regulatory strategy.\n\nBurixafor successfully completed a Phase 2 clinical trial in multiple myeloma\nlast year, providing a foundation for further evaluation in hematologic\nindications such as AML and SCD. Based on its clinical profile to date,\nBurixafor may have potential applicability in additional hematologic\nindications.\n\nThe parties intend to conduct in vivo validation studies and, subject to\nfurther agreement, may advance selected programs into IND-enabling studies and\nclinical trials. The parties also intend to secure funding to support the\nadvancement of future clinical development.\n\nFurther details regarding development plans, budget, intellectual property,\nand commercialization will be determined in a subsequent definitive agreement.\n\nA representative of Exicure commented, “This agreement represents an\nimportant step in expanding the evaluation of Burixafor in combination\napproaches across multiple indications.”\n\nAbout Exicure, Inc.\n\nExicure, Inc. (Nasdaq: XCUR) has historically been an early-stage\nbiotechnology company focused on developing nucleic acid therapies targeting\nribonucleic acid against validated targets. Following its restructuring and\nsuspension of clinical and development activities, the Company is exploring\nstrategic alternatives to maximize stockholder value. In January 2025, it\nacquired a clinical-stage biotechnology company developing therapeutics for\nhematologic diseases. The Company’s lead program in development is being\nevaluated for its ability to improve stem cell mobilization in multiple\nmyeloma, sickle cell disease, and in support of cell and gene therapy. For\nmore information, visit www.exicuretx.com.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. All statements in this\npress release other than statements of historical fact may be deemed forward\nlooking including, but not limited to, statements regarding: the Company’s\ncurrent business plans and objectives, including the pursuit of strategic\nalternatives to maximize stockholder value, the timing of the equity\ninvestment closing and potential additional equity investment and the Nasdaq\nHearings Panel process and potential results. Words such as “plans,”\n“expects,” “will,” “anticipates,” “continue,” “advance,”\n“believes,” “target,” “may,” “intend,” “could,” and other\nwords and terms of similar meaning and expression are intended to identify\nforward-looking statements, although not all forward-looking statements\ncontain such terms. Forward-looking statements are based on management’s\ncurrent beliefs and assumptions that are subject to risks and uncertainties\nand are not guarantees of future performance. For a discussion of other risks\nand uncertainties, and other important factors, any of which could cause the\nCompany’s actual results to differ from those contained in the\nforward-looking statements, see the section titled “Risk Factors” in the\nCompany’s Annual Report on Form 10-K for the year ended December 31, 2025\nfiled with the Securities and Exchange Commission in connection with this\npress release, as updated by the Company’s subsequent filings with the\nSecurities and Exchange Commission. All information in this press release is\nas of the date of the release, and the Company undertakes no duty to update\nthis information or to publicly announce the results of any revisions to any\nof such statements to reflect future events or developments, except as\nrequired by law.\n\nMedia Contact\n\nExicure, Inc.\npr@exicuretx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/3a5f958d-422c-4a97-a96d-cf06f640b587)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX35Fh38","title":"Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)","author":"Globe Newswire","ticker":"XCUR","created":"2026-04-22T23:54:21.097Z","tickers":["XCUR"],"exchange":"NASDAQ","article_body":"CHICAGO, April 22, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) today\nannounced that it has entered into a co-development agreement with Adbiotech\nCo., Ltd. (KOSDAQ: 179530), a Korea-based biotechnology company, to explore\ncombination therapies based on Burixafor (GPC-100) across multiple therapeutic\nareas.\n\nThe collaboration will focus on evaluating combination strategies involving\nBurixafor (GPC-100) in indications including sickle cell disease (SCD), acute\nmyeloid leukemia (AML), and solid tumors.\n\nUnder the agreement, Adbiotech will conduct in vivo studies and support\npreclinical validation and translational research, while Exicure will provide\nBurixafor and lead clinical and regulatory strategy.\n\nBurixafor successfully completed a Phase 2 clinical trial in multiple myeloma\nlast year, providing a foundation for further evaluation in hematologic\nindications such as AML and SCD. Based on its clinical profile to date,\nBurixafor may have potential applicability in additional hematologic\nindications.\n\nThe parties intend to conduct in vivo validation studies and, subject to\nfurther agreement, may advance selected programs into IND-enabling studies and\nclinical trials. The parties also intend to secure funding to support the\nadvancement of future clinical development.\n\nFurther details regarding development plans, budget, intellectual property,\nand commercialization will be determined in a subsequent definitive agreement.\n\nA representative of Exicure commented, “This agreement represents an\nimportant step in expanding the evaluation of Burixafor in combination\napproaches across multiple indications.”\n\nAbout Exicure, Inc.\n\nExicure, Inc. (Nasdaq: XCUR) has historically been an early-stage\nbiotechnology company focused on developing nucleic acid therapies targeting\nribonucleic acid against validated targets. Following its restructuring and\nsuspension of clinical and development activities, the Company is exploring\nstrategic alternatives to maximize stockholder value. In January 2025, it\nacquired a clinical-stage biotechnology company developing therapeutics for\nhematologic diseases. The Company’s lead program in development is being\nevaluated for its ability to improve stem cell mobilization in multiple\nmyeloma, sickle cell disease, and in support of cell and gene therapy. For\nmore information, visit www.exicuretx.com.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. All statements in this\npress release other than statements of historical fact may be deemed forward\nlooking including, but not limited to, statements regarding: the Company’s\ncurrent business plans and objectives, including the pursuit of strategic\nalternatives to maximize stockholder value, the timing of the equity\ninvestment closing and potential additional equity investment and the Nasdaq\nHearings Panel process and potential results. Words such as “plans,”\n“expects,” “will,” “anticipates,” “continue,” “advance,”\n“believes,” “target,” “may,” “intend,” “could,” and other\nwords and terms of similar meaning and expression are intended to identify\nforward-looking statements, although not all forward-looking statements\ncontain such terms. Forward-looking statements are based on management’s\ncurrent beliefs and assumptions that are subject to risks and uncertainties\nand are not guarantees of future performance. For a discussion of other risks\nand uncertainties, and other important factors, any of which could cause the\nCompany’s actual results to differ from those contained in the\nforward-looking statements, see the section titled “Risk Factors” in the\nCompany’s Annual Report on Form 10-K for the year ended December 31, 2025\nfiled with the Securities and Exchange Commission in connection with this\npress release, as updated by the Company’s subsequent filings with the\nSecurities and Exchange Commission. All information in this press release is\nas of the date of the release, and the Company undertakes no duty to update\nthis information or to publicly announce the results of any revisions to any\nof such statements to reflect future events or developments, except as\nrequired by law.\n\nMedia Contact\n\nExicure, Inc.\npr@exicuretx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/3a5f958d-422c-4a97-a96d-cf06f640b587)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-04-22T23:54:21.137076858Z","server_sent_at_ms":1776902061137},"received_at":"2026-04-22T23:54:21.195Z","source_url":null},"analysis":{"id":"4190","press_release_id":"5715","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["non-binding agreement requiring subsequent definitive deal","funding for clinical advancement not yet secured"],"eventType":"partnership","narrative":"Exicure entered a co-development agreement with Korea-based Adbiotech to study combination therapies for Burixafor in sickle cell disease, AML, and solid tumors.\n\nUnder the non-binding framework, Adbiotech will conduct in vivo studies while Exicure leads regulatory strategy and supplies the drug, which previously completed a Phase 2 trial in multiple myeloma.\n\nNo financial terms were disclosed, and the parties noted that a definitive agreement is required to finalize development plans and budgets.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Non-binding LOI provides a path forward for Burixafor, but lacks financial commitment or definitive terms."},"keyFigures":{"drugName":"Burixafor (GPC-100)","phaseOfTrial":"Phase 2"},"quotedText":"This agreement represents an important step in expanding the evaluation of Burixafor in combination approaches across multiple indications.","namedEntities":{"people":[],"products":["Burixafor","GPC-100"],"companies":[{"name":"Exicure, Inc.","ticker":"XCUR"},{"name":"Adbiotech Co., Ltd.","ticker":"179530","relationship":"partner"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"The agreement is non-binding with no financial terms or secured funding disclosed, and the scope is currently limited to in vivo studies requiring a subsequent definitive agreement to proceed."},"tickerRelevance":{"others":[{"ticker":"179530","relevance":"partner"}],"primary":"XCUR"},"eventTypeSecondary":[]},"event_type":"partnership","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Exicure entered a co-development agreement with Korea-based Adbiotech to study combination therapies for Burixafor in sickle cell disease, AML, and solid tumors.\n\nUnder the non-binding framework, Adbiotech will conduct in vivo studies while Exicure leads regulatory strategy and supplies the drug, which previously completed a Phase 2 trial in multiple myeloma.\n\nNo financial terms were disclosed, and the parties noted that a definitive agreement is required to finalize development plans and budgets.","key_figures":{"drugName":"Burixafor (GPC-100)","phaseOfTrial":"Phase 2"},"named_entities":{"people":[],"products":["Burixafor","GPC-100"],"companies":[{"name":"Exicure, Inc.","ticker":"XCUR"},{"name":"Adbiotech Co., Ltd.","ticker":"179530","relationship":"partner"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:2f2748f0fcc8c4f2","schema_hash":"sha256:ad96b863d7123008","created_at":"2026-04-23T01:21:38.187Z","global_importance":3,"audience_relevance":3,"importance_components":{"method":"backfill-heuristic","signals":{"bodyLong":false,"headlineTier1":false,"tickerCovered":false,"hadSignificance":false},"version":1,"computedAt":"2026-04-27T11:52:54.557Z"}},"durationMs":145732,"modelName":"glm-4.7"}}